NCT01502410 · REGISTRY CONDITION SEARCH

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2018-06-26

This phase II trial studies how well sorafenib tosylate works in treating younger patients with relapsed or refractory rhabdomyosarcoma, Wilms tumor, liver cancer, or thyroid cancer. Sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Objective Response by RECIST Criteria v 1.1

→

outcome · POSTED

Progression-free Survival According to RECIST Version 1.1

→

outcome · POSTED

The Number of Patients Who Experience at Least One Grade 3 or Higher CTC Version 4 Toxicity,

→

outcome · POSTED

Pharmacokinetic (PK) Parameters of Sorafenib Tosylate

→

outcome · POSTED

Change in VEGF and VEGFR-2

→

outcome · POSTED

Presence of BRAF Mutation or RET/PTC Rearrangement

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Patients must have had histologic verification of one of the malignancies listed below at original diagnosis or at relapse: * Rhabdomyosarcoma (RMS) * Wilms tumor * Hepatocellular carcinoma (HCC) * Papillary thyroid carcinoma (PTC) * Patients must have relapsed or refractory disease (RMS, Wilms tumor, HCC, PTC) * Patients must have radiographically measurable disease; measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan that can be accurately measured with the longest diameter a minimum of 10 mm in at least one dimension (CT scan slice thickness no greater than 5 mm) * The following do not qualify as measurable disease: * Malignant fluid collections (e.g., ascites, pleural effusions) * Bone marrow infiltration * Lesions only detected by nuclear medicine studies (e.g., bone, gallium, or positron emission tomography \[PET\] scans) * Elevated tumor markers in plasma or cerebrospinal fluid(CSF) * Previously radiated lesions that have not demonstrated clear progression post radiation * Leptomeningeal lesions that do not meet the requirements noted above * Patients with HCC must be relapsed or refractory to conventional chemotherapy * Patients with PTC must be refractory to radioactive iodine (RAI) * Patient's current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life * Patients with known metastasis to the brain will be excluded from trial participation unless treated surgically or with radiotherapy and stable with no recurrent lesions for at least 3 months * Rhabdomyosarcoma and Wilms strata: patients must be ≥ 24 months and ≤ 30 years of age at study enrollment * Hepatocellular carcinoma (HCC): patients must be ≥ 24 months and \< 18 years of age at study enrollment * Papillary thyroid carcinoma (PTC): patients must be ≥ 24 months and ≤ 21 years of age at study enrollment * Patients must have a Lansky or Karnofsky performance status score of ≥ 50%, corresponding to ECOG categories 0, 1, or 2 * Use Karnofsky for patients \> 16 years of age and Lansky for patients ≤ 16 years of age * Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score * Peripheral absolute neutrophil count (ANC) ≥ 1,000/μL * Platelet count ≥ 75,000/μL (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to enrollment) * Hemoglobin 8.0 g/dL (may receive red blood cell\[RBC\] transfusions) * Creatinine clearance or radioisotope glomerular filtration rate(GFR) 70 mL/min OR a serum creatinine based on age/gender as follows: * 0.8 mg/dL (2 to \< 6 years of age) * 1.0 mg/dL (6 to \< 10 years of age) * 1.2 mg/dL (10 to \< 13 years of age) * 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to \< 16 years of age) * 1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age) * Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age * SGPT (ALT) ≤ 135 U/L (for the purpose of this study, the ULN for SGPT is 45 U/L) * PT, PTT, and INR \< 1.5 times ULN * Normal serum lipase and amylase (per institutional normal values) * No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \> 94% if there is clinical indication for determination * A blood pressure (BP) ≤ the 95\^th percentile for age, height, and gender; and not receiving medication for treatment of hypertension * Patients who are pregnant or breast-feeding are not eligible * Negative pregnancy tests must be obtained in girls who are post-menarchal * Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method beginning at the signing of the informed consent until at least 30 days after the last dose of the study drug * Patients with clinical symptoms of hepatic encephalopathy or ascites are not eligible * Patients who have an uncontrolled infection are not eligible * Patients with evidence of bleeding diathesis are not eligible * Patients with known Gilbert syndrome are not eligible * Patients who, in the opinion of the investigator, may not be able to comply with the safety-monitoring requirements of the study are not eligible * No concurrent chemotherapy, radiation therapy, immunomodulating agents, or other investigational agents * Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study * Patients with solid tumors must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea) * At least 7 days must have elapsed since the completion of therapy with a growth factor (at least 14 days must have elapsed after receiving pegfilgrastim) * At least 7 days must have elapsed since completion of therapy with a biologic agent; * For agents that have known adverse events occurring beyond 7 days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur * At least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody * At least 2 weeks must have elapsed since local palliative radiotherapy (XRT) (small port); ≥ 3 months must have elapsed if prior craniospinal XRT was received, if ≥ 50% of the pelvis was irradiated, or if TBI was received; ≥ 6 weeks must have elapsed if other substantial bone marrow irradiation was given * No evidence of active graft-vs-host disease and ≥ 2 months must have elapsed since transplant (stem cell transplant or rescue without total-body irradiation) * For patients with papillary thyroid carcinoma (PTC) only: ≥ 3 weeks from prior radioiodine (RAI) treatment * Patients requiring corticosteroids that have not been on a stable or decreasing dose of corticosteroid for 7 days prior to enrollment are not eligible * Patients who are currently receiving another investigational drug are not eligible * Patients who are currently receiving other anti-cancer agents are not eligible * Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post transplant are not eligible for this trial * Patients who take cytochrome P450 enzyme-inducing anti-epileptic drugs (phenytoin, carbamazepine, or phenobarbital), rifampin, grapefruit juice, or St. Johns wort will not be eligible for the trial * Patients who have received prior treatment with sorafenib are not eligible * Patients must not be on therapeutic anti-coagulation; * Prophylactic anticoagulation (i.e., low-dose warfarin) of venous or arterial devices is allowed provided that the requirements for prothrombin time(PT), partial thromboplastin time(PTT), and international normalized ratio(INR) are met
healthy Volunteers: false
maximum Age: 30 Years
minimum Age: 2 Years
sex: ALL
std Ages: CHILD
ADULT

Treatment arms and interventions

arm Groups

description
Patients with relapsed or refractory rhabdomyosarcoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28 pharmacological study: Optional correlative studies laboratory biomarker analysis: Optional correlative studies
intervention Names
Drug: sorafenib tosylate
Other: pharmacological study
Other: laboratory biomarker analysis
label
Group 1 Relapsed/Refractory Rhabdomyosarcoma
type
EXPERIMENTAL
description
Patients with relapsed or refractory Wilms tumor receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28 pharmacological study: Optional correlative studies laboratory biomarker analysis: Optional correlative studies
intervention Names
Drug: sorafenib tosylate
Other: pharmacological study
Other: laboratory biomarker analysis
label
Group 2 Relapsed/Refractory Wilms tumor
type
EXPERIMENTAL
description
Patients with relapsed or refractory hepatocellular carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28 pharmacological study: Optional correlative studies laboratory biomarker analysis: Optional correlative studies
intervention Names
Drug: sorafenib tosylate
Other: pharmacological study
Other: laboratory biomarker analysis
label
Group 3 Relapsed/Refractory hepatocellular carcinoma
type
EXPERIMENTAL
description
Patients with relapsed or refractory papillary thyroid carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28 pharmacological study: Optional correlative studies laboratory biomarker analysis: Optional correlative studies
intervention Names
Drug: sorafenib tosylate
Other: pharmacological study
Other: laboratory biomarker analysis
label
Group 4 Papillary thyroid carcinoma
type
EXPERIMENTAL

interventions

arm Group Labels
Group 1 Relapsed/Refractory Rhabdomyosarcoma
Group 2 Relapsed/Refractory Wilms tumor
Group 3 Relapsed/Refractory hepatocellular carcinoma
Group 4 Papillary thyroid carcinoma
description
Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
name
sorafenib tosylate
other Names
BAY 43-9006
BAY 43-9006 Tosylate Salt
BAY 54-9085
Nexavar
SFN
type
DRUG
arm Group Labels
Group 1 Relapsed/Refractory Rhabdomyosarcoma
Group 2 Relapsed/Refractory Wilms tumor
Group 3 Relapsed/Refractory hepatocellular carcinoma
Group 4 Papillary thyroid carcinoma
description
Optional correlative studies
name
pharmacological study
other Names
pharmacological studies
type
OTHER
arm Group Labels
Group 1 Relapsed/Refractory Rhabdomyosarcoma
Group 2 Relapsed/Refractory Wilms tumor
Group 3 Relapsed/Refractory hepatocellular carcinoma
Group 4 Papillary thyroid carcinoma
description
Optional correlative studies
name
laboratory biomarker analysis
type
OTHER

Study design

allocation

NON_RANDOMIZED

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 20
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Response rates will be calculated as the number of evaluable patients who are responders. Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): Disappearance of all target lesions, Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD, Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started and Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
measure
Objective Response by RECIST Criteria v 1.1
time Frame
6 cycles (168 days)

secondary Outcomes

description
Percent probability of being progression free six months following enrollment. Progression-free interval (PFI) will be calculated as the date of enrollment until the end PFI date, where that date is calculated as the date of disease progression, date of death, date of removal of all tumors by surgery or last patient contact, whichever occurs first.
measure
Progression-free Survival According to RECIST Version 1.1
time Frame
Six months after enrollment
description
Each patient is classified as having experienced grade 3 or higher CTC version 4 toxicity if at any time during protocol therapy such an event is observed for the individual.
measure
The Number of Patients Who Experience at Least One Grade 3 or Higher CTC Version 4 Toxicity,
time Frame
six cycles of chemotherapy; expected to be 126 days of treatment
description
The trough sorafenib concentration is evaluated at baseline (prior to administration of Sorafenib) and 12 hours after administration of Sorafenib on day 15, day 56, day 112 and day 168 in micrograms/ml.
measure
Pharmacokinetic (PK) Parameters of Sorafenib Tosylate
time Frame
Prior to administration of Sorafenib (baseline), day 15, day 56, day 112 and day 168
description
Serum VEGF and VEGF receptor 2 Concentration is evaluated at baseline and at day 15 of protocol therapy in picograms/ml.
measure
Change in VEGF and VEGFR-2
time Frame
Prior to the administration of sorafenib (baseline) and day 15 of protocol therapy
description
Descriptive statistics including mean, median, standard deviation, and range will be calculated for baseline for patients with PTC, TG and TG antibody, and presence of BRAF mutation or RET/PTC rearrangement.
measure
Presence of BRAF Mutation or RET/PTC Rearrangement
time Frame
At baseline

Full study description

brief Summary: This phase II trial studies how well sorafenib tosylate works in treating younger patients with relapsed or refractory rhabdomyosarcoma, Wilms tumor, liver cancer, or thyroid cancer. Sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
detailed Description: PRIMARY OBJECTIVES: I. To determine the objective response rate to sorafenib tosylate (sorafenib) in children with relapsed or refractory rhabdomyosarcoma, Wilms tumor, hepatocellular carcinoma (HCC), or papillary thyroid carcinoma (PTC). SECONDARY OBJECTIVES: I. To further define and describe the toxicities of sorafenib administered on an oral, twice-daily continuous schedule. II. To further characterize the pharmacokinetics of sorafenib in children with refractory cancer. III. To estimate the progression-free survival on sorafenib for rhabdomyosarcoma, Wilms tumor, and hepatocellular carcinoma and compare to a group of patients enrolled on selected closed Phase II studies of Children Oncology Group (COG). IV. To assess the biologic activity of sorafenib on vascular endothelial growth factor (VEGF) and soluble vascular endothelial growth factor receptor-2 (VEGFR-2) in peripheral blood samples. (Exploratory) V. To evaluate the presence of BRAF mutations and RET/PTC rearrangements in patients with PTC. (Exploratory) OUTLINE: This is a multicenter study. Patients are stratified according to diagnosis (rhabdomyosarcoma vs Wilms tumor vs hepatocellular carcinoma vs papillary thyroid carcinoma). Patients receive sorafenib tosylate orally (PO) twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for pharmacokinetic studies, and VEGF and VEGFR-2 analysis by ELISA. Previously collected formalin-fixed paraffin-embedded tissue samples, from patients with papillary thyroid carcinoma, are also analyzed for BRAF mutation and RET/PTC rearrangements by PCR. After completion of study treatment, patients are followed up for up to 5 years.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-2d02f911e18e59bb3463
requested nct id
NCT01502410
primary nct id
NCT01502410
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Kidney+Tumors&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
0f0b1d47d700cf556d6212d53b7849c30874e411dbc1a4cfc2cbeef7e5d70ca8
payload sha256
cc0983ab43826c1715b6d972dd7689a22cb0f9c1d5975b9ff1694e1476c3505a
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-2d02f911e18e59bb3463
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01502410
occurrences
context exact
NCT01502410
end
11
exact text
NCT01502410
start
0
offset unit
unicode_code_points
query cond
Childhood Kidney Tumors
query disease state id
ds-childhood-kidney-tumors
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-kidney-tumors-000.json
source file sha256
0f0b1d47d700cf556d6212d53b7849c30874e411dbc1a4cfc2cbeef7e5d70ca8
source json pointer
/studies/11/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
0c7bc8c996f87453a2495d091a50c43347d5d4cc10fbd4ac543f73dff21f646d
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Kidney+Tumors&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-4346366bf07a1f90e404
requested nct id
NCT01502410
primary nct id
NCT01502410
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Thyroid+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
18bf4f98a808754b540d2c97b42e70959cdae0c75ae03261cbea3e49b40d31cd
payload sha256
6db8a2c513366ffd4e8a69f6b40d9465227434d27142f13583bd396ccb51a726
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-4346366bf07a1f90e404
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01502410
occurrences
context exact
NCT01502410
end
11
exact text
NCT01502410
start
0
offset unit
unicode_code_points
query cond
Childhood Thyroid Cancer
query disease state id
ds-thyroid-cancer-pediatric
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-thyroid-cancer-000.json
source file sha256
18bf4f98a808754b540d2c97b42e70959cdae0c75ae03261cbea3e49b40d31cd
source json pointer
/studies/1/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
0c7bc8c996f87453a2495d091a50c43347d5d4cc10fbd4ac543f73dff21f646d
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Thyroid+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-ebfd715563545c93bd27
requested nct id
NCT01502410
primary nct id
NCT01502410
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Liver+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
9d7960d89169a453f1ac7b2a50046538e920fc46c1e81576f7eac42f88243453
payload sha256
2173bd4ce04cd7d84d7960a8ba76c56a79b67ce2d23e84ab831100c0381238f2
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-ebfd715563545c93bd27
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01502410
occurrences
context exact
NCT01502410
end
11
exact text
NCT01502410
start
0
offset unit
unicode_code_points
query cond
Childhood Liver Cancer
query disease state id
ds-liver-cancer-pediatric
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-liver-cancer-000.json
source file sha256
9d7960d89169a453f1ac7b2a50046538e920fc46c1e81576f7eac42f88243453
source json pointer
/studies/4/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
0c7bc8c996f87453a2495d091a50c43347d5d4cc10fbd4ac543f73dff21f646d
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Childhood+Liver+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice